News Releases

2021-02/07
Interim Analysis Results of the Phase I clinical trial of UBIA’s COVID-19 vaccine UB-612
1
2020-12/10
United BioPharma won the “2020 National Talent Development Award''
2
2020-11/11
United BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital Herpes
3
2020-09/28
COVAXX Initiates Phase 1 Clinical Trial of COVID-19 Vaccine UB-612 in Taiwan
4
2020-08/21
United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
5
2020-08/05
United BioPharma Received Approval from Taiwan FDA for a Phase 1 Trial with UB-421 Subcutaneous Formulation in HIV-1 Infected Patients
6
2020-07/13
Dr. Flossie Wong-Staal, a board member of UBI since 1995, passed away on Wednesday, July 8th, at the age of 73 due to pneumonia
7
2020-05/19
Minister of Health and Welfare led the delegation to visit United BioPharma for the COVID-19 vaccine development program
8
2020-04/27
United BioPharma Received Approval from TFDA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
9
2021-02/07
Interim Analysis Results of the Phase I clinical trial of UBIA’s COVID-19 vaccine UB-612
1
2020-12/10
United BioPharma won the “2020 National Talent Development Award''
2
2020-11/11
United BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital Herpes
3
2020-09/28
COVAXX Initiates Phase 1 Clinical Trial of COVID-19 Vaccine UB-612 in Taiwan
4
2020-08/21
United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
5
2020-08/05
United BioPharma Received Approval from Taiwan FDA for a Phase 1 Trial with UB-421 Subcutaneous Formulation in HIV-1 Infected Patients
6
2020-07/13
Dr. Flossie Wong-Staal, a board member of UBI since 1995, passed away on Wednesday, July 8th, at the age of 73 due to pneumonia
7
2020-05/19
Minister of Health and Welfare led the delegation to visit United BioPharma for the COVID-19 vaccine development program
8
2020-04/27
United BioPharma Received Approval from TFDA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
9
Received certificate of occupancy for UBP’s eight-story (7000 sq Meter) headquarter building based in Huko, Hsinchu county designed for administrative, R&D and large scale protein drug manufacturing activities 2016-12/15
Filed IND for UB-921 (Anti-HER2 monoclonal antibody) phase I clinical trial to TFDA 2016-12/15
UBP entered into a licensing agreement with UBI US Holdings LLC and UBI IP Holdings, the subsidiary of United Biomedical, Inc (UBI) for exclusive US and ROW (ex-Asia) rights for development and commercialization of UB-421 2016-08/15
UB-421 for HIV treatment won the 12th National Innovation Prize given by Taiwan Biotechnology Strategic Planning Association 2015-12/15
IND submission of a phase I clinical trial for UB-621, an Anti-HSV-gD antibody, was approved by Taiwan Food and Drug Administration (TFDA) 2015-11/15
United BioPharma received approval for UB-421 Phase II clinical trial for HAART substitution treatment in treatment stabilized HIV patients from Taiwan Food and Drug Administration (TFDA) 2015-06/15
Filed an IND submission of a phase II clinical trial for HAART substitution therapy in treatment stabilized HIV patients with Taiwan Food and Drug Administration (TFDA) 2015-02/15
UB-421 product received Gold Medal award for 2014 Pharmaceutical Technology Research and Development jointly given by Ministry of Economic Affairs and Minitry of Health, Taiwan 2014-12/15
Filed an IND submission of a phase I clinical trial for UB-621, an anti-HSV-gD antibody, with Taiwan Food and Drug Administration (TFDA) 2014-12/15
United BioPharma Licenses Innovative Antibody Drug 8D6 for Asthma and Allergy Treatment from Academia Sinica 2014-12/14
United BioPharma, Inc. Copyright (c) 2021